Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ibuprofen  COVID-19 treatment studies for Ibuprofen  C19 studies: Ibuprofen  Ibuprofen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -21% Improvement Relative Risk Ventilation -12% ICU admission -40% c19early.org/ib Rinott et al. Ibuprofen for COVID-19 EARLY TREATMENT Favors ibuprofen Favors control
Ibuprofen use and clinical outcomes in COVID-19 patients
Rinott et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.06.003
Rinott et al., Ibuprofen use and clinical outcomes in COVID-19 patients, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.06.003
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 403 COVID-19 cases in Israel, showing no significant difference in outcomes with ibuprofen use. Patients were asked about ibuprofen use starting a week before diagnosis of COVID-19 - treatment time may have been early, late, or prophylactic.
risk of death, 21.1% higher, RR 1.21, p = 0.73, treatment 3 of 87 (3.4%), control 9 of 316 (2.8%).
risk of mechanical ventilation, 11.8% higher, RR 1.12, p = 0.77, treatment 4 of 87 (4.6%), control 13 of 316 (4.1%).
risk of ICU admission, 39.7% higher, RR 1.40, p = 0.56, treatment 5 of 87 (5.7%), control 13 of 316 (4.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rinott et al., 30 Sep 2020, retrospective, Israel, peer-reviewed, median age 45.0, 5 authors, study period 15 March, 2020 - 15 April, 2020.
Contact: youngsteri@shamir.gov.il.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIbuprofenAll
Abstract: Clinical Microbiology and Infection 26 (2020) 1259.e5e1259.e7 Contents lists available at ScienceDirect Clinical Microbiology and Infection journal homepage: www.clinicalmicrobiologyandinfection.com Research note Ibuprofen use and clinical outcomes in COVID-19 patients E. Rinott 1, E. Kozer 2, 3, Y. Shapira 3, 4, A. Bar-Haim 5, I. Youngster 3, 6, * 1) Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Paediatric Emergency Unit, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel 3) Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 4) Division of Internal Medicine, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel 5) Molecular Laboratory, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel 6) Paediatric Infectious Diseases, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel 2) a r t i c l e i n f o a b s t r a c t Article history: Received 12 May 2020 Received in revised form 3 June 2020 Accepted 6 June 2020 Available online 12 June 2020 Objective: It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. Methods: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. Results: The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventynine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen. Conclusions: In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic. E. Rinott, Clin Microbiol Infect 2020;26:1259.e5e1259.e7 © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Editor: L. Scudeller Keywords: Antipyretics Coronavirus disease 2019 Disease severity Ibuprofen Paracetamol
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit